The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

Resverlogix

Status and phase: Completed; Phase 2

Conditions: Diabetes

Treatments: Drug: RVX000222; Drug: Placebo, RVX000222

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01728467

RVX222-CS-010

Alfred Study No. 409/12 (Other Identifier)

Details and patient eligibility

About

This study builds on data that high-density lipoprotein (HDL) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. The primary objective of this study is to determine the effects of RVX000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test (OGTT).

Enrollment: 20 patients

Sex: Male

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males aged 18-70 years, inclusive
• Body mass index (BMI): 25-40 kg/m2
• HDL cholesterol plasma levels: ≤1.4 mmol/L
• Pre-diabetes: Either impaired fasting glucose (IFG; 6.1-6.9mmol/L) or impaired glucose tolerance (IGT; 2 hour OGTT glucose 7.8-11.0mmol/L, WHO classification) as measured at Visit 1
• No current use or need for prescription or over-the-counter medication within four days of Visit 1
• Have given signed informed consent to participate in the study

Exclusion criteria

• Identification of any other medical condition requiring immediate therapeutic intervention
• Has received any over-the-counter medication including vitamins, herbal, or dietary supplements within four days of Visit 1 unless prior approval from the Investigator
• Tobacco use within six months of Visit 1 (including cigarettes, pipes, chewing tobacco)
• Elective surgery requiring general anaesthesia during the course of the study
• Clinically significant heart disease at Visit 1
• Clinically significant abnormal ECG at Visit 1
• Evidence of renal impairment defined as serum creatinine >1.5 mg/dL (133 μmol/L) or creatinine clearance of <60 mL/min
• History of hypertension or supine SBP >160mmHg or DBP >95mmHg as measured at Visit 1
• Evidence of type 2 diabetes (fasting plasma glucose ≥7.0mmol/L; 2 hour OGTT glucose ≥11.1mmol/L)
• Evidence of liver disease defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin >1.5 x upper limit of normal (ULN) at Visit 1
• History of malignancy within past 5 years
• History or evidence of drug or alcohol abuse within 12 months of Visit 1
• Use of other investigational drugs and/or devices at the time of enrolment, or within 30 days of Visit 1
• History of non-compliance to medical regimens or unwillingness to comply with the study protocol
• Any condition that in the opinion of the Investigators would confound the evaluation and interpretation of the data
• Persons directly involved in the execution of the protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

20 participants in 2 patient groups, including a placebo group

RVX000222, 200 mg daily

Experimental group

Treatment:

Drug: RVX000222

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo, RVX000222